ReviewFrontiers in pharmacology2020
Current Status of Septic Cardiomyopathy: Basic Science and Clinical Progress.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 2 syntheses or guidelines pooled it, 126 citations in OpenAlex.
- The role of esmolol in sepsis: a meta-analysis based on randomized controlled trials.BMC anesthesiology · 2024Pooled it
- Venoarterial extracorporeal membrane oxygenation as mechanical circulatory support in adult septic shock: a systematic review and meta-analysis with individual participant data meta-regression analysis.Critical care (London, England) · 2021Pooled it
- Evaluating the effects of Esmolol on cardiac function in patients with Septic cardiomyopathy by Speck-tracking echocardiography-a randomized controlled trial.BMC anesthesiology · 2023Trial
- Effect Evaluation of Norepinephrine on Cardiac Function in Patients with Sepsis by Cardiac Ultrasound Imaging.Computational and mathematical methods in medicine · 2022Trial
- Association of Baseline and Dynamic Changes in Growth Differentiation Factor-15 Changes with Longitudinal Myocardial Function in Sepsis.Journal of cardiovascular development and disease · 2026Article
- ADAMTS4 mediates LPS-induced cardiac injury and myocardial fibrosis through proteolytic cleavage of TSP1.Clinical and translational medicine · 2026Article
- Methyltransferase METTL1 Upregulates USF2 in a m7G-Dependent Manner to Accelerate Septic Cardiomyopathy by Inactivating PINK1/Parkin-Mediated Mitophagy.Cardiovascular toxicology · 2026Article
- Article
- Overexpression of Circular RNA circTTN Promotes Ferroptosis in Sepsis-Induced Cardiomyopathy.Journal of cellular and molecular medicine · 2026Article
- Expression characteristics of peripheral blood miR-146a and TLR4 in septic cardiomyopathy: Correlations with myocardial injury markers and cardiac function classification.Pakistan journal of medical sciences · 2026Article
- Conducting polymer-stabilized nanozymes alleviate sepsis-induced myocardial injury by inhibiting iron accumulation and lipid peroxidation.Nature communications · 2026Article
- Multi-omics analysis identifies NFIL3 as a hypoxia-associated immune regulator in septic cardiomyopathy.Frontiers in immunology · 2026Article
- Early Predictive Value of Peripheral Inflammatory Index Combined with High-Sensitivity Troponin T for Sepsis-Induced Cardiomyopathy.Mediterranean journal of hematology and infectious diseases · 2026Article
- Interpretable gradient boosting machine model for predicting in-hospital mortality in sepsis-induced myocardial injury: a multicenter development, validation, and web-based clinical implementation.Frontiers in cardiovascular medicine · 2026Article
- Ketogenic diet strategy in patients with sepsis: a multicentre prospective randomised interventional trial protocol.BMJ open · 2025Article
- Targeting Lcn2 to Inhibit Myocardial Cell Ferroptosis is a Potential Therapy for Alleviating Septic Cardiomyopathy.Inflammation · 2025Article
- Sepsis toxicity network reconstruction-Dynamic signaling and multi-organ injury: A review.Biomolecules & biomedicine · 2025Review
- Predictive value of combined inflammatory markers for septic cardiomyopathy: a retrospective study.BMC infectious diseases · 2025Article
- Hemodynamic Patterns in Septic Cardiomyopathy: Insights From Echocardiographic Parameters and Biomarker Analysis.Cureus · 2025Article
- c-FLIP Protects Cardiac Microcirculation in Sepsis-Induced Myocardial Dysfunction Via FUNDC1-Mediated Regulation of Mitochondrial Autophagy.JACC. Basic to translational science · 2025Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Septic cardiomyopathy (SCM) is a complication that is sepsis-associated cardiovascular failure. In the last few decades, there is progress in diagnosis and treatment despite the lack of consistent diagnostic criteria. According to current studies, several hypotheses about pathogenic mechanisms have been revealed to elucidate the pathophysiological characteristics of SCM. The objective of this manuscript is to review literature from the past 5 years to provide an overview of current knowledge on pathogenesis, diagnosis and treatment in SCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.